Recurrent inactivating RASA2 mutations in melanoma

Rand Arafeh (First Author), Nouar Qutob (Co-Author), Rafi Emmanuel (Co-Author), Alona Keren-Paz (Co-Author), Jason Madore (Co-Author), Abdel Elkahloun (Co-Author), James S. Wilmott (Co-Author), Jared J. Gartner (Co-Author), Antonella Di Pizio (Co-Author), Sabina Winograd-Katz (Co-Author), Sivasish Sindiri (Co-Author), Ron Rotkopf (Co-Author), Ken Dutton-Regester (Co-Author), Peter Johansson (Co-Author), Antonia L. Pritchard (Co-Author), Nicola Waddell (Co-Author), Victoria K. Hill (Co-Author), Jimmy C. Lin (Co-Author), Yael Hevroni (Co-Author), Steven A. Rosenberg (Co-Author)Javed Khan (Co-Author), Shifra Ben-Dor (Co-Author), Masha Y. Niv (Co-Author), Igor Ulitsky (Co-Author), Graham J. Mann (Co-Author), Richard A. Scolyer (Co-Author), Nicholas K. Hayward (Co-Author), Yardena Samuels* (Last Author)

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Abstract

Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in ≥30% of human melanomas and was associated with reduced patient survival. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer.

Original languageEnglish
Pages (from-to)1408-1410
Number of pages3
JournalNature Genetics
Volume47
Issue number12
DOIs
StatePublished - 1 Dec 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'Recurrent inactivating RASA2 mutations in melanoma'. Together they form a unique fingerprint.

Cite this